Science
Overview
Microbion’s novel technology is centered around developing a new class of antimicrobial compounds for the treatment of serious diseases, including resistant and difficult to treat infections, and conditions that involve chronic or dysfunctional inflammation. Microbion’s compounds, including pravibismane, have demonstrated antibacterial efficacy against a broad range of Gram-negative and Gram-positive bacteria, and their associated biofilms. Microbial biofilms have been associated with a wide variety of persistent infections which respond very poorly to conventional antibiotic therapy. Pravibismane has also demonstrated potent anti-inflammatory activity. This unique triad of broad spectrum antimicrobial actions and immunomodulatory activity represents first-in-class and best-in-class potential, providing an innovative clinical approach to treating a wide variety of challenging, serious diseases.